Novel reference material to standardize gene therapy applications

The growing popularity in the gene therapy community of using recombinant adeno-associated virus (rAAV) vectors as vehicles to transfer a gene of interest into a host cell has led to increasing numbers of human clinical trials and animal studies with rAAV.

In the past, the absence of standardization—such as for rAAV potency and dosing—have made it difficult for researchers and clinicians to compare their protocols and the results of gene therapy experiments.

The availability of this rAAV reference standard will allow vector parameters to be expressed in common units, vector doses administered by different investigators to be normalized to an agreed-upon standard, and laboratories to calibrate their internal standards to a common reference material.

Martin Lock, from the Gene Therapy Program at the University of Pennsylvania (Philadelphia) and colleagues from several major medical and research institutions around the world, describe the development of reference standard in the article “Characterization of a Recombinant Adeno-Associated Virus Type 2 Reference Standard Material.”

The American Type Culture Collection will make the rAAV2 reference standard material available to the scientific community. AAV serotype 2 was selected as the basis for the reference material because it is the best characterized AAV subtype. The material has been thoroughly analyzed and found to be free of microbial contamination. During development of the rAAV2 reference standard samples were distributed to 16 laboratories worldwide for extensive analysis and characterization.

“The development of a reference standard for an AAV vector is an important step towards the eventual commercial development of this important vector platform,” says James M. Wilson, MD, PhD, Editor-in-Chief of Human Gene Therapy, and Head of the Gene Therapy Program, Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, in Philadelphia.

Human Gene Therapy, the Official Journal of the European Society of Gene and Cell Therapy, British Society for Gene Therapy, French Society of Cell and Gene Therapy, German Society of Gene Therapy, and five other gene therapy societies is an authoritative peer-reviewed journal published monthly in print and online that presents reports on the transfer and expression of genes in mammals, including humans. Related topics include improvements in vector development, delivery systems, and animal models, particularly in the areas of cancer, heart disease, viral disease, genetic disease, and neurological disease, as well as ethical, legal, and regulatory issues related to the gene transfer in humans. Tables of content and a free sample issue may be viewed online at www.liebertpub.com/hum

Mary Ann Liebert, Inc. (www.liebertpub.com), is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Tissue Engineering, Stem Cells and Development, and Cellular Reprogramming. Its biotechnology trade magazine, Genetic Engineering & Biotechnology News (GEN), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 60 journals, books, and newsmagazines is available at our website (www.liebertpub.com).

Mary Ann Liebert, Inc. 140 Huguenot St., New Rochelle, NY 10801-5215 www.liebertpub.com

Phone: (914) 740-2100 (800) M-LIEBERT Fax: (914) 740-2101